Abstract:Background/Introduction In patients with cardiogenic shock (CS), a combination of Impella-a percutaneous ventricular assist device with a catheter-type micro-axial heart pump-and venoarterial extracorporeal membrane oxygenation (ECPELLA) has been reported to have a better prognosis compared to venoarterial extracorporeal membrane oxygenation (VA-ECMO) alone, although it was associated with more complications. In contemporary clinical practice, ECPELLA has often been used in place of VA-ECMO alone. However, in many cases of acute myocardial infarction (AMI) with CS, there is controversy regarding the prioritization of Impella or VA-ECMO installation. Purpose The current study aims to clarify the factors of Impella use before VA-ECMO, the impact of the timing of Impella insertion (before or after VA-ECMO) for 30-day mortality, and major adverse events (MAEs) in the two groups. Methods The Japanese registry for Percutaneous Ventricular Assist Device (J-PVAD) Registry is a nationwide registry enrolling 5,718 consecutive Japanese patients treated with Impella between February 2020 and December 2022. The current study population consisted of 1,082 patients with AMI complicated by CS excluding cardiopulmonary arrest on arrival or using only Impella, who were divided into 2 groups; Impella use before and after VA-ECMO. Results Among the current study population, 323 patients (30%) used Impella before VA-ECMO, and 759 patients (70%) used Impella after VA-ECMO. Patients who used Impella before VA-ECMO were older (72 vs. 68 years old, P<0.0001) and had higher left ventricular ejection fraction (LVEF) (30 vs 20 %, P<0.0001), lower lactate level (5.6 vs 9.1 mmol/L, P<0.0001), and more often ST-elevation myocardial infarction (MI) (82% vs 76%, P<0.0001), whereas those patients had less often out-of-hospital cardiac arrest (OHCA) (13% vs 45%, P<0.0001), in-hospital cardiac arrest (IHCA) (27% vs 63%, P<0.0001), and prior heart failure (9.5% vs 16%, P=0.006). The factors of Impella use before VA-ECMO were 75 years or older, dyslipidemia, the absence of OHCA, the absence of IHCA, the absence of prior MI, and the absence of LVEF less than 30%. The cumulative 30-day incidence of all-cause death was 46.2% in patients with Impella use before VA-ECMO and 53.4% in those with Impella use after VA-ECMO (Log-rank P=0.02). After adjusting confounders, there was no excess risk of Impella use before VA-ECMO relative to Impella use after VA-ECMO (adjusted HR, 0.87; 95%CI, 0.55-1.37; P=0.55). Regarding major adverse events, hemolysis was significantly more frequent in patients with Impella use before VA-ECMO, while stroke was significantly more common in patients with Impella use after VA-ECMO. Conclusions The prognosis with AMI complicated by CS requiring ECPELLA remained poor. The 30-day mortality was lower in patients with Impella use before VA-ECMO compared to after VA-ECMO. However, after adjusting for confounders, there was no difference between the two groups.

Left ventricular unloading via percutaneous assist device during extracorporeal membrane oxygenation in acute myocardial infarction and cardiac arrest

Meta-Analysis Comparing Venoarterial Extracorporeal Membrane Oxygenation With or Without Impella in Patients With Cardiogenic Shock

Impact of extracorporeal cardiopulmonary resuscitation with ECPELLA on improvement of short-term survival in patients with refractory cardiac arrest

ECPELLA: Beyond a Left Ventricular Venting Strategy When to Unload the Left Ventricle and How to Decide

Comparison Of Outcomes In Patients With Acute Myocardial Infarction Complicated With Cardiogenic Shock Treated With Ecpella Versus Va-ecmo With Iabp

Benefit of veno-arterial extracorporeal membrane oxygenation combined with Impella (ECpella) therapy in acute coronary syndrome with cardiogenic shock

Impella Versus Intra-Aortic Balloon Pump in Patients With Cardiogenic Shock Treated With Venoarterial Extracorporeal Membrane Oxygenation: An Observational Study

Influence of timing of impella insertion on the prognosis of acute myocardial infarction complicated with cardiogenic shock requiring ECPELLA

Impella as unloading strategy during VA-ECMO: systematic review and meta-analysis

Impact of extracorporeal CPR with transcatheter heart pump support (ECPELLA) on improvement of short-term survival and neurological outcome in patients with refractory cardiac arrest - A single-site retrospective cohort study

The Use Of Ecpella In Cardiogenic Shock, An Umbrella Meta-Analysis

Utility of venoarterial extracorporeal membrane oxygenation in patients with acute myocardial infarction complicated by cardiogenic shock

EC-VAD: Combined Use of Extracorporeal Membrane Oxygenation and Percutaneous Microaxial Pump Left Ventricular Assist Device

Novel Left Ventricular Unloading Strategies in Patients on Peripheral Venoarterial Extracorporeal Membrane Oxygenation Support

In-Hospital Mortality in Patients With Cardiogenic Shock Requiring Veno-Arterial Extracorporeal Membrane Oxygenation With Concomitant Use of Impella vs. Intra-Aortic Balloon Pump - A Retrospective Cohort Study Using a Japanese Claims-Based Database

Cardiac ECMO: changing role in times of Impella and ventricular assist devices?

Steady Flow Left Ventricle Unloading Is Superior to Pulsatile Pressure Augmentation Venting During Venoarterial Extracorporeal Membrane Oxygenation Support

Abstract 12772: In Hospital Outcomes With Extracorporeal Membrane Oxygenation Alone vs Combined With Percutaneous Left Ventricular Assist Device

Mortality in patients with normal left ventricular function requiring emergency VA-ECMO for postcardiotomy cardiogenic shock due to coronary malperfusion

Scrutinizing the Role of Venoarterial Extracorporeal Membrane Oxygenation: Has Clinical Practice Outpaced the Evidence?

Mechanical left ventricular unloading in cardiogenic shock treated with venoarterial extracorporeal membrane oxygenation: a systematic review and meta-analysis